| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Division of Pulmonary Diseases, Geneva University Hospital, Geneva, and 2 La Chaux-de-Fonds, Neuchâtel, Switzerland.
CORRESPONDENCE: J-P. Janssens, Centre antituberculeux, Hôpital Cantonal Universitaire, 1211 Geneva 14, Switzerland. Fax: 41 223799929. E-mail: Jean-Paul.Janssens@hcuge.ch
Keywords: Ethambutol, hepatotoxicity, latent tuberculous infection, multidrug-resistant tuberculosis, pyrazinamide, treatment
Received: January 16, 2005
Accepted May 31, 2005
 |
ABSTRACT |
|---|
 TOP ABSTRACT PATIENTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
In total, 12 consecutive contacts, all of African origin and aged 38±5 yrs, were treated with daily PZA (23±4 mg·kg–1) and EMB (17±4 mg·kg–1) at Geneva University Hospital outpatient clinic (Switzerland), as a result of contact-tracing procedures for two patients with contagious MDR-TB.
Clinical status and liver function tests (aspartate aminotransferase (ALAT) and alanine aminotransferase (ASAT)) were monitored monthly. In seven cases (58%) treatment was discontinued after a median of 119 days, due to hepatic toxicity in six cases (ALAT or ASAT elevation more than four times the upper normal limit), and gastrointestinal symptoms in one case.
In conclusion, combined pyrazinamide and ethambutol for latent tuberculosis infection may be associated with a high risk of hepatic toxicity, and warrants close monitoring. There is clearly a need for alternative preventive treatments for contacts exposed to multidrug-resistant tuberculosis.
Multidrug-resistant tuberculosis (MDR-TB) is defined as a tuberculous infection by bacilli showing simultaneous resistance to at least isoniazid (INH) and rifampicin (RIF). In Switzerland, between 1999–2000, 1.2% of all declared cases of tuberculosis (TB) were MDR-TB, and all were foreign-born 1. Maintaining a high index of suspicion in patients with risk-factors for MDR-TB, rapid identification (whenever possible through genotyping for resistance to RIF), isolation of active cases, directly observed therapy implementation, and treatment of latent tuberculosis infection (LTBI) caused by exposure to cases of MDR-TB are all essential to control the spread of resistant bacilli. The current USA guidelines recommend the use of pyrazinamide (PZA) and either ethambutol (EMB) or a fluoroquinolone as a first-line treatment (before results of susceptibility testing for infecting strain are available) for adults with LTBI related to MDR-TB, for 6–12 months 2. These recommendations are supported by expert opinion, but not by controlled trials 3.
Recent reports have highlighted the potential hepatotoxicity of combined treatment with RIF and PZA for LTBI (5.8%) 4–6. Due to the lower hepatic toxicity of RIF alone, rather than that of PZA, the question of the toxicity of PZA and its' acceptability in a prophylactic treatment has been raised 7, 8. To date, information as to the toxicity of PZA in combination with either EMB or a fluoroquinolone is scarce 9–11.
This case series describes the high prevalence of drug-induced hepatitis associated with treatment of latent MDR-TB infection by PZA and EMB in adults.
|
PATIENTS AND METHODS |
|---|
|
TOPABSTRACTPATIENTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
In total, 12 out of the 18 contacts identified were followed in Geneva University Hospital, while six left the Geneva area and were lost to follow-up. All contacts originated from either sub-Saharan Africa (n = 9) or Eritrea (n = 3). All contacts identified had a tuberculin skin test (TST) induration >10 mm (17±4 mm; TST 2 units of RT 23® Tuberculin; Statens Serum Institut, Copenhagen, Denmark), and definite close contact with either of the two index cases. None of the contacts were aware of a previous TST.
On the basis of the joint American Thoracic Society (ATS) and Centers for Disease Control and Prevention (CDC) guidelines for treatment of LTBI in contacts exposed to MDR-TB cases, a combined treatment of PZA and EMB was initiated for 9 months 2. Intended doses were 20–25 mg·kg–1·day–1 and 15–20 mg·kg–1·day–1 for PZA and EMB, respectively. This choice was in agreement with susceptibility testing of Mycobacterium tuberculosis strains of index cases. All treatments were initiated between September 2003 and March 2004. Cases were announced to the Swiss national registry of pharmacovigilance.
Liver function testing (ASAT: aspartate aminotransferase; and ALAT: alanine aminotransferase) was performed before the beginning of the chemoprophylaxis, after 2 weeks and then on a monthly basis.
Treatment was discontinued if increase in ALAT or ASAT was greater than four times the upper limit of normal (ALAT: 42 U·L–1; ASAT: 42 U·L–1), or if the patient presented drug-related adverse effects.
Systematic serology for viral hepatitis was not performed, since initial ASAT and ALAT were within normal values in all subjects.
|
RESULTS |
|---|
|
TOPABSTRACTPATIENTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. Median age of contacts was 38 yrs (range 31–48 yrs). All had baseline values of ALAT and ASAT within the normal range. None had any comorbidity or medication, albeit for one patient with chronic (undiagnosed) hepatitis B infection and systemic hypertension, treated by diltiazem, hydrochlorothiazide and valsartan. Daily doses of PZA and EMB were mean±SD (range): 23±4 mg·kg–1 (17–33) and 17±3 mg·kg–1 (13–22), respectively.
|
) and two of these cases had gastrointestinal (GI) symptoms. One patient had a mild elevation of liver enzymes associated with GI symptoms requiring discontinuation of medication. No other side-effects were reported, albeit for unspecific visual disturbances in one case with normal visual evoked potentials. Among the six patients with liver toxicity, peak values ranged from 82–1,338 U·L–1 for ALAT and 164–2,030 U·L–1 for ASAT. For all contacts, liver enzyme values returned to normal after discontinuation of medication.
|
DISCUSSION |
|---|
|
TOPABSTRACTPATIENTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
As previously mentioned, current USA guidelines recommend the use of PZA with either EMB or a fluoroquinolone as first-line treatment for adults with LTBI related to MDR-TB, for 6–12 months 2. The present report is, to the current authors' knowledge, the first to describe a high rate of drug-induced hepatitis in contacts treated in this context with a combination of PZA and EMB. Previous publications have described high rates of drug-induced hepatitis in contacts treated by PZA with either levofloxacin (47%) or ofloxacin (25–41%) 9–11. Median time to peak increase in ASAT and/or ASAT was approximately 4 weeks in these three studies, with a wide variability (drug-induced hepatitis occurring up to 25 weeks after beginning of treatment). Liver tests returned to normal within 3–5 weeks after discontinuing treatment 10.
EMB is not considered as incriminated in drug-induced hepatitis, and, thus, liver toxicity in this series is most probably exclusively PZA related 7, 8. However, the rate of drug-induced hepatitis in standard treatment for active TB (INH, RIF, PZA and EMB) is 
3% 7. Thus, rates described for combinations of PZA and either RIF (8–9%) 4–6, fluoroquinolones (25–47%) 9–11, or EMB are surprising and yet unexplained. In the present report, treatment was interrupted after a median period of 4 months, thus, prolonged treatment with PZA when compared with the 2 months of standard treatment for active TB may contribute to the increased incidence of liver toxicity. However, drug-induced hepatitis occurred earlier in cases treated with PZA and a fluoroquinolone. Risk factors for PZA-induced hepatitis have been identified in patients undergoing treatment for active TB, such as sex (female), older age (
60 yrs of age), birth in Asia and HIV infection 7, 12. However, none of these risk factors were relevant in the present study.
Two additional comments must be made as to the results presented. First, all contacts treated for LTBI underwent monthly monitoring of ASAT and ALAT. This is not recommended as a routine measure in treatment for active TB or LTBI 2, 13. The relevance of a mild asymptomatic increase in ASAT and ALAT may, thus, be questioned, and could be overestimated in the data presented. However, documenting ASAT or ALAT levels three times or more above the upper limit of normal level (if symptoms present) or five times above (if asymptomatic) is considered as a mandatory reason for interrupting all potentially hepatotoxic tuberculostatic drugs in ATS/CDC guidelines 13. Thus, the attitude adopted is in agreement with recent recommendations and previous publications 7, 12. Secondly, all contacts were of African origin, most of them from sub-Saharan Africa. The unexpectedly high rate of drug-induced hepatitis could, thus, be related to the ethnic background of the subjects studied. However, to the present authors' knowledge there is no support for this hypothesis in the previous publications relative to treatment for either active TB or LTBI.
Although any conclusion based on available evidence is preliminary, the frequency of drug-induced hepatitis in published reports of patients exposed to MDR-TB, and treated for LTBI with PZA and either EMB or fluoroquinolones, is preoccupying. Drug-induced hepatitis can occur several months after the beginning of treatment. Furthermore, marked increases in ASAT and/or ALAT can be virtually asymptomatic. Systematic monthly monitoring of patients and their liver enzymes is mandatory in this setting.
Furthermore, alternative regimens to those presently recommended must be envisaged and studied, because of the increasing frequency of multidrug-resistant tuberculosis and, thus, the increasing need for an effective treatment for latent tuberculosis infection in these cases.
|
REFERENCES |
|---|
|
TOPABSTRACTPATIENTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  K. C. Chang, C. C. Leung, W. W. Yew, T. Y. Lau, and C. M. Tam Hepatotoxicity of Pyrazinamide: Cohort and Case-Control Analyses Am. J. Respir. Crit. Care Med., June 15, 2008; 177(12): 1391 - 1396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Saukkonen, D. L. Cohn, R. M. Jasmer, S. Schenker, J. A. Jereb, C. M. Nolan, C. A. Peloquin, F. M. Gordin, D. Nunes, D. B. Strader, et al. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 935 - 952. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
